Back to Search

Precision Promise Platform Trial for Metastatic Pancreatic Cancer

  • Protocol Number: 201911159
  • Principal Investigator: Lim, Kian-Huat
  • Cancer Types: Gastrointestinal

Learn more about this study at: clinicaltrials.gov

For more information on this trial, contact us here:

Phone
800-600-3606
Email
info@ccadmin.wustl.edu

Brief Summary

Precision Promise is a multi-center, seamless Phase 2/3 platform trial designed to evaluate multiple regimens in metastatic pancreatic cancer.

Primary Objectives

To compare each investigational arm versus standard of care (SOC) for superiority in overall survival in 1st and/or 2nd line metastatic pancreatic cancer patients and determine which, if any, patients benefit from each investigational arm.

Secondary Objectives

To determine short and long-term safety signals of each investigational arm in pancreatic cancer patients vs. SOC.
To determine progression-free survival (PFS) for each investigational arm vs. SOC.
Rates of overall response, CR, and PR; duration of overall response, CR or PR (whichever occurs first).
Rate of clinical benefit; duration of clinical benefit.

Protocol Interventions

Gemcitabine combined with nab-paclitaxel, Dose -mFOLFIRINOX, Dose – Pamrevlumab combined with gemcitabine and nab-paclitaxel, Dose- Canakinumab and Spartalizumab combined with nab-paclitaxel and gemcitabine, Drug: Dose -SM-88